This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Non-randomised prospective with concurrent controls design. It appears that the patients were recruited from different institutions and 'group living' regimes in Sundsvall but this is not clear. Baseline quality-of-life data were collected and assumptions were made about disease progression. No patients were lost to follow-up.
Analysis of effectiveness
Effectiveness was measured in terms of the quality of life-years gained of the patients in the different residence regimes. Their degree of dementia was measured using the global deterioration scale (GDS) and were ultimately based on the judgements of the project manager. Their rating on the GDS (between 4 and 7) was then converted into a 'utility' score (using a computer program) on the index of well-being (IWB) scale. A static model assumed that different residence regimes had no effect on the progression of the disease whilst a dynamic assumed that group living slowed the deterioration. A Markov model was used to model the progression of the disease in the different residence regimes. The progression of disease was modelled over an eight year period. The IB. scores over this period were discounted at 4%. The numbers of patients in GDS stages 4-7 were compared for the different residence regimes over this period. The probability of progression was based upon real changes in the first year. There seemed little need to control for age, sex, etc. since the patients in the three groups were very similar regarding these characteristics.
Effectiveness results
The probability of progression through the GDS was lowest for the group living patients and highest for those patients living at home. The gain in QALY terms according to IWB scores were: Group living = 3.27; Home living = 2.99; Institutional care = 2.89; Home and institutional = 2.95.
Modelling
A Markov model was constructed to describe the progression of dementia in each of the residence types and the implied use of resources.
Measure of benefits used in the economic analysis
QALYs based on assumptions about how GDS scores map into IWB utilities.
Direct costs
Quantities and costs were measured separately but not reported separately. The number of hours were recorded for: the use of group living (by the group living patients), institutional care, social services with home help, home care with nurses, remuneration paid to relatives caring for patients at home, and living at a home for the aged. These figures were multiplied by per item costs and added to overhead costs. The costs were estimated for the eight year survival period and discounted at 4%.1987 prices were used. Total costs were calculated using a Markov model.
